

The Honorable Patty Murray
United States Senate
154 Russell Senate Office Building
Washington, DC 20510

July 10, 2026

Dear Senator Murray:

On behalf of the Endocrine Society and our membership of approximately 18,000 scientists, clinicians, and allied health professionals, I am writing to thank you for your leadership in opposing the Office of Management and Budget's (OMB) proposed revisions to 2 CFR Part 200, the Regulation for Federal Financial Assistance, commonly known as the Uniform Guidance. We appreciate your efforts, alongside your Senate Democratic colleagues, to urge OMB to withdraw this harmful proposal and protect the integrity of the federal grantmaking process.

Your recent highlights many of the same concerns the Endocrine Society raised [in our comments](#) to OMB. We are particularly aligned on the following issues:

- **Displacement of scientific merit-** We agree that requiring political appointees to conduct a pre-issuance review of whether an award “demonstrably advance[s] the President’s policy priorities” would fundamentally alter the longstanding merit-based framework that has established a proven track record of success for federally supported scientific research, undermining Congressional intent that research funding be awarded based on scientific merit and public health goals.
- **Mid-award termination authority-** We share your concern that permitting termination based on vague criteria, including on the undefined “national interest” standard—would inject damaging uncertainty into multi-year scientific projects. Researchers cannot plan, hire, or make long-term commitments to patients in clinical trials in an environment where grants are subject to immediate termination on such grounds.
- **New administrative burdens-** Your letter also highlights the extensive new administrative requirements proposed by OMB. We also assert that provisions such as requiring written justification for every payment and drawdown request would impose significant administrative burdens that would disproportionately impact smaller institutions—directly contradicting OMB’s own stated goal of reducing recipient burden.

Finally, we share your concern regarding the rushed timeline for implementation. OMB has proposed sweeping changes affecting the entire medical research enterprise while providing only a brief comment period before a targeted implementation date of October 1, 2026. Such changes



warrant comprehensive stakeholder input, including from Congress, professional scientific and medical organizations, research institutions, and the public.

Thank you again for your leadership on this critical issue and for your efforts to protect medical research. Should OMB move forward with the proposal, we would welcome the opportunity to work with you and your colleagues to prevent implementation. Please do not hesitate to contact the Endocrine Society's Director of Science Policy at jlaakso@endocrine.org if you or your staff have any questions about how our members would be affected by these changes and if we can be of assistance to you.

Sincerely,

A handwritten signature in black ink, appearing to read "Nanette Santoro".

Nanette Santoro, MD
President, Endocrine Society